BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang Y, Zhou Y, Lu M, An Y, Li R, Chen Y, Lu DR, Jin L, Zhou WP, Qian J, Wang HY. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma. Mol Carcinog. 2012;51:515-521. [PMID: 21656577 DOI: 10.1002/mc.20805] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Quintanal-Villalonga Á, Ojeda-Márquez L, Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, Carnero A, Ferrer I, Molina-Pinelo S, Paz-Ares L. The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. Sci Rep 2018;8:2394. [PMID: 29402970 DOI: 10.1038/s41598-018-20570-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
2 Shiu BH, Hsieh MH, Ting WC, Chou MC, Chang LC, Huang CC, Su SC, Yang SF. Impact of FGFR4 Gene Polymorphism on the Progression of Colorectal Cancer. Diagnostics (Basel) 2021;11:978. [PMID: 34071523 DOI: 10.3390/diagnostics11060978] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Peng T, Sun Y, Lv Z, Zhang Z, Su Q, Wu H, Zhang W, Yuan W, Zuo L, Shi L, Zhang LF, Zhou X, Mi Y. Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer. Sci Rep 2021;11:1373. [PMID: 33446698 DOI: 10.1038/s41598-020-80146-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Quintanal-Villalonga Á, Carranza-Carranza A, Meléndez R, Ferrer I, Molina-Pinelo S, Paz-Ares L. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. Clin Lung Cancer 2017;18:667-674.e1. [PMID: 28583379 DOI: 10.1016/j.cllc.2017.05.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
5 Wang H, Yang J, Zhang K, Liu J, Li Y, Su W, Song N. Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets. Front Pharmacol 2021;12:650388. [PMID: 33935756 DOI: 10.3389/fphar.2021.650388] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Xiong SW, Ma J, Feng F, Fu W, Shu SR, Ma T, Wu C, Liu GC, Zhu J. Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis. Oncotarget 2017;8:25300-9. [PMID: 28445975 DOI: 10.18632/oncotarget.15811] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Zhang HF, Zhao KJ, Yang PF, Fang YB, Zhang YH, Liu JM, Huang QH. Association between fibroblast growth factor receptor 4 Gly388Arg polymorphism and ischaemic stroke. J Int Med Res 2012;40:1708-14. [PMID: 23206452 DOI: 10.1177/030006051204000509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Fang HM, Tian G, Zhou LJ, Zhou HY, Fang YZ. FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer. Acta Pharmacol Sin 2013;34:549-54. [PMID: 23524567 DOI: 10.1038/aps.2012.206] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cha Z, Zang Y, Guo H, Gu H, Tu X, Song H, Qian B. RETRACTED ARTICLE: Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma. Mol Biol Rep 2014;41:1165-70. [DOI: 10.1007/s11033-013-2963-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Sheu MJ, Hsieh MJ, Chiang WL, Yang SF, Lee HL, Lee LM, Yeh CB. Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. PLoS One 2015;10:e0122961. [PMID: 25860955 DOI: 10.1371/journal.pone.0122961] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
11 Li S, Qian J, Yang Y, Zhao W, Dai J, Bei JX, Foo JN, McLaren PJ, Li Z, Yang J. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet. 2012;8:e1002791. [PMID: 22807686 DOI: 10.1371/journal.pgen.1002791] [Cited by in Crossref: 128] [Cited by in F6Publishing: 130] [Article Influence: 12.8] [Reference Citation Analysis]
12 Jiang Y, Sun S, Wei W, Ren Y, Liu J, Pang D. Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province. Oncotarget 2015;6:34023-9. [PMID: 26431494 DOI: 10.18632/oncotarget.5850] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
13 Li JP, Huang HC, Yang PJ, Chang CY, Chao YH, Tsao TC, Huang H, Hung YC, Hsieh MJ, Yang SF. FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan. Int J Environ Res Public Health 2020;17:E5694. [PMID: 32781755 DOI: 10.3390/ijerph17165694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148 [PMID: 30949443 DOI: 10.5306/wjco.v10.i3.136] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
15 Moazeni-Roodi A, Sarabandi S, Karami S, Hashemi M, Ghavami S. An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer. Biosci Rep 2020;40:BSR20192051. [PMID: 33017009 DOI: 10.1042/BSR20192051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kim JH, Jeong SY, Jang HJ, Park ST, Kim HS. FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis. Front Oncol 2021;11:762528. [PMID: 34737965 DOI: 10.3389/fonc.2021.762528] [Reference Citation Analysis]
17 Liu WC, Wu IC, Chiu YC, Tseng KC, Chen CY, Chiu HC, Cheng PN, Chang TT. Genotyping of immune-related loci associated with delayed HBeAg seroconversion in immune-active chronic hepatitis B patients. Antiviral Res 2020;176:104719. [PMID: 32004619 DOI: 10.1016/j.antiviral.2020.104719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhu Q, Liu T. Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study. Mol Biol Rep. 2012;39:8679-8685. [PMID: 22696188 DOI: 10.1007/s11033-012-1723-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
19 Chen Z, Jiang L, Liang L, Koral K, Zhang Q, Zhao L, Lu S, Tao J. The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma. Am J Pathol 2021;191:1180-92. [PMID: 34000282 DOI: 10.1016/j.ajpath.2021.04.014] [Reference Citation Analysis]
20 Ma L, Zhang H, Han C, Tong D, Zhang M, Yao Y, Luo Y, Liu X. Fibroblast growth factor receptor 4 polymorphisms and susceptibility to coronary artery disease. DNA Cell Biol. 2012;31:1064-1069. [PMID: 22313031 DOI: 10.1089/dna.2011.1552] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
21 Heinzle C, Erdem Z, Paur J, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B. Is fibroblast growth factor receptor 4 a suitable target of cancer therapy? Curr Pharm Des. 2014;20:2881-2898. [PMID: 23944363 DOI: 10.2174/13816128113199990594] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
22 Shen YY, Lu YC, Shen DP, Liu YJ, Su XY, Zhu GS, Yin XL, Ni XZ. Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients. World J Gastroenterol 2013; 19(28): 4568-4575 [PMID: 23901234 DOI: 10.3748/wjg.v19.i28.4568] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
23 Gao L, Feng Z, Li Q, Li L, Chen L, Xiao T. Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma. Tumour Biol. 2014;35:2997-3002. [PMID: 24248544 DOI: 10.1007/s13277-013-1386-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]